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Abstract
OBJECTIVE: To investigate the effect of Sanhuangy-
ilong decoction plus methotrexate (MTX) on Inter-
feron gamma (IFN-γ) and tumor necrosis factor al-
pha (TNF-α) in the serum and synovial fluid of rheu-
matoid arthritis (RA) patients with damp-heat-ob-
struction symptom pattern, Sanhuangyilong decoc-
tion and the role of TNF-α and IFN-γ in the develop-
ment of RA.
METHODS: RA inpatients with damp-heat-obstruc-
tion symptom pattern (partly with knee joint effu-
sion) were selected as the research subjects. Before
the treatment, healthy subjects and osteoarthritis
(OA) patients with knee joint effusion were as-
signed to the serum control group and the synovial
fluid control group, respectively; during the treat-
ment, RA patients with damp-heat-obstruction
symptom pattern were divided into two groups:
one is combined group that was administered San-
huangyilong decoction plus MTX; the other group
was MTX group that received MTX only. The expres-
sion levels of TNF-α and IFN-γ in the serum and sy-
novial fluid were measured with enzyme-linked im-
munosorbent assay (ELISA) before and after the
treatment, and the peripheral blood levels of eryth-
rocyte sedimentation rate (ESR), C-reactive protein
(CRP) and disease activity score in 28 joints (DAS28)
were determined.
RESULTS: Before treatment, the serum levels of
TNF-α and IFN-γ in the RA patients with damp-
heat-obstruction symptom pattern were higher
than those in healthy control group (P < 0.05).The
expression levels of TNF-α and IFN-γ in the synovial
fluid of the RA patients were higher than those in
the serum of the RA patients (P < 0.05). The expres-
sion levels of TNF-α and IFN-γ in the synovial fluid
of the RA patients were higher than those of the sy-
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novial fluid of the osteoarthritis patients (P < 0.05).
The expression of TNF-α and IFN-γ in the serum
and synovial fluid of the RA patients had no correla-
tion with the inflammatory activity index ESR, CRP,
or DAS28 (P > 0.05). After 2 weeks of treatment, the
expression level of TNF-α and IFN-γ in the com-
bined group had increased, although the differ-
ence was not statistically significant (P > 0.05); in
contrast, ESR, CRP, and DAS28 decreased, and the
difference was statistically significant (P < 0.01). Af-
ter 4 weeks of therapy, TNF-alpha and IFN-γ, ESR,
CRP, and DAS28 in the combined group decreased
compared with the before-treatment levels (P <
0.01). After 2 w of treatment, the differences in the
TNF-α and IFN-γ expression levels in the combined
group were not statistically significant (P > 0.05)
compared with that in the MTX group, although
there were statistically significant differences in the
ESR, CRP, and DAS28 (P < 0.05). After 4 weeks of
treatment, differences in TNF-α, IFN-γ, ESR, CRP, and
DAS28 in the combined group compared with MTX
group were statistically significant (P < 0.01).
CONCLUSION: TNF-α and IFN-γ might be involved
in the development of RA. The RA patients with
damp-heat-obstruction symptom pattern show
better benefits from the treatment of Sanhuangy-
ilong decoction plus MTX, and the treatment is su-
perior to that of using MTX only.
© 2016 JTCM. All rights reserved.
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INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune
disease characterised by chronic, erosive arthritis,
which primarily involves symmetrical polyarticular
swelling, pain, stiffness and multi-system involvement.
The pathogenesis of RA is not clear. Research reports
show that Th1 (T helper 1) and Th17 (T helper 17),
the main pro-inflammatory Th subgroup, induce the
pathogenesis of RA,1 and many cytokines secreted by
them play an important role in the pathogenesis of
RA. Interferon gamma (IFN-γ) is the major cytokine
secreted by Th1 cells; however, tumor necrosis factor al-
pha (TNF-α) is predominantly secreted by Th17 cells.
Both cytokines play a specific role in the pathogenesis
of RA. The erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP) level are commonly used to
reflect the disease activity of RA as clinical and labora-
tory indexes, and the disease activity score in 28 joints
(DAS28)2 is a comprehensive index for evaluating RA
disease activity.
Based on the symptoms patterns minified in RA pa-
tients, in terms of theory of Traditional Chinese Medi-
cine (TCM), RA is often diagnosed as the obstruction
of Qi and blood in the meridians due to the invision of
external pathogenic wind, cold, wet and heat, manifest-
ed as soreness, pain, numbness, a heavy sensation,
swelling of the joints and limbs, limitation of move-
ment and the formation of chronic inflammation. The
Bi (symptom) pattern in Plain Questions3 states that
"if the wind, cold and dampness invade the body to-
gether, Bi (symptom) pattern might develop", demon-
strating that Bi (symptom) pattern is associated with
several pathogenic Qi. Shuo Wen Jie Zi4 which was
written in the Han Dynasty, includes the interpreta-
tion of "Bi, the pathogenic dampness", which indicates
that pathogenic dampness is a major cause of rheuma-
tism. The highest moisture levels in China occur in the
Southwest. From 1993-1995, meteorologists investigat-
ed Beijing, Shanghai, Chengdu, and Guangzhou,
which are in the north, southeast, southwest, and
south of China, respectively, and the results show that
the annual average relative humidity is 53% , 75% ,
82% and 75%, respectively.5 The view that "dampness
and heat, arthralgia" is described as early as in the "syn-
opsis of prescriptions of the Golden Chamber",6 includ-
ing the hypotheses that "patients suffering from patho-
genic dampness have pain and fever" and "dampness
being the disease, [which is] manifested as pain and fe-
ver of the body". Zhang et al 7 noted that the damp-
ness-heat symptom pattern was closely related with the
occurrence, development and prognosis of a variety of
rheumatic diseases. In Traditional Chinese Medicine
(TCM), RA is divided into 6 symptom patterns:
damp-heat, phlegm and blood stasis, a deficiency of Qi
and Yin, cold dampness, blood stasis obstruction and
deficiency of spleen and kidney. Jiang et al 8 analysed
the distribution of TCM symptom patterns in 475
in-patients with RA, finding that most of the occur-
rences were of damp-heat symptom pattern, which ac-
counted for 41.7% of the cases. Le et al 9 retrospective-
ly analysed the relationship between the TCM symp-
tom pattern type and the immune index in 143 RA pa-
tients, showing that the anti-cyclic citrullinated pep-
tide antibody and rheumatoid factor (RF) have the
highest positive rate in damp-heat symptom pattern.
Damp-heat symptom pattern predominates in the ac-
tive stage of RA, and RA patients with damp-heat
symptom pattern according to the standard were select-
ed as the subjects of the study.
After years of study, our research team found that the
Sanhuangyilong decoction displays a certain effective-
ness in the treatment of RA with high activity by elimi-
nating dampness.10 This project aimed to investigate
the effects of Sanhuangyilong decoction combined
with MTX on TNF-α and IFN-γ, and the their role in
the development of RA.
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MATERIALS ANDMETHODS
Clinical data
From January 2011 to January 2013, 118 RA inpa-
tients diagnosed with damp-heat symptom pattern
were registered in the Department of Rheumatism
Combined Traditional Chinese and Western Medicine
(Rheumatic Disease Medical Centre, Chengdu Mili-
tary Region), General Hospital of Chengdu Military
Region. A total of 28 cases were excluded for various
reasons, including failing to obtain a sample during
treatment, detecting the emergence of complications
and poor patient compliance; the remaining 90 cases
were assigned to the RA patient group. Thirty outpa-
tients or inpatients suffering from osteoarthritis (OA)
with knee joint synovial fluid were assigned to the OA
group with synovial fluid, and 30 healthy people
served as the healthy control group.
The study was approved by Hospital ethics committee,
and registered in the World Health Organization data-
base at the General Hospital of Chengdu Military Area
Command Chinese People's Liberation Army (ChiC-
TR-TRC-14004520). Informed consent was obtained
from all participants.
Diagnostic criteria
We used two Western Medicine diagnostic criteria for
rheumatoid arthritis: American College of Rheumatolo-
gy (ACR) 198711 and/or ACR/The European League
Against Rheumatism (EULAR )2009.12 The diagnosis
of osteoarthritis (OA) refers to the diagnostic criteria of
ACR 1986.13
We used a Traditional Chinese Medicine (TCM) diag-
nostic criterion for identifying the subtypes of Bi symp-
tom pattern, which were identified by the following 3
major symptoms, 2 secondary symptoms and tongue
and pulse examinations. The main symptoms were as
follows: joint redness, swelling, heat and pain; joint
stiffness; joint swelling; joint tenderness and joint de-
formation. The secondary symptoms were as follows:
joint heaviness; local joint inflammation; and thirst
without a desire to drink. The appearance of the
tongue and pulse readings were as follows: red tongue
or dark red tongue; a whitish, greasy, furry or yellow
tongue coating; and soft and rapid pulse or slippery
and rapid pulse.
Inclusion and exclusion criteria
The following inclusion criteria were used in the study:
(a) a diagnosis of RA and OA; and (b) a TCM diagno-
sis of damp-heat symptom pattern type of Bi symptom
pattern. The researchers obtained the approval of the
ethics committee of the General Hospital of the Cheng-
du Military Region of the People's Liberation Army of
China. The subjects provided their signed informed
consent.
The following exclusion criteria were used in the study:
(a) pregnant or lactating women and subjects with aller-
gies; (b) an association with other autoimmune diseas-
es; (c) serious heart, brain, liver, kidney, blood, endocrine
and gastrointestinal diseases; (d) disturbance of con-
sciousness ormental abnormality; or (e) other reasons.
Grouping and treating
The RA group comprised 90 RA patients, in which 28
patients with knee joint synovial fluid were assigned to
the RA group with synovial fluid. The RA patient
group included 80 females and 10 males, aged 45-65 ye-
ars old. The average age was (56 ± 7) years, the course of
the disease was 0.25-40 years, and the average course
of the disease was (13 ± 13) years. During the treat-
ment, we followed the provisions of the ethics commit-
tee and distributed random numbers with random ta-
bles in accordance with a randomisation method; the
RA patients were divided into the combined group of
45 patients and the MTX group of 45 patients. The
combined group included 38 females and 7 males,
with a mean age of (56 ± 8) years old; the MTX group
included 37 females and 8 males, with a mean age of
(55 ± 8) years old. There were no significant differenc-
es between the two groups in age and gender (P >
0.05).
The healthy control group included 30 age-and
sex-matched healthy persons, including 26 females and
4 males, aged 46-64 years old with a mean age of (55 ±
7) years.
The OA group included 30 age-and sex-matched osteo-
arthritis patients with knee joint synovial fluid, includ-
ing 27 females and 3 males, aged 48-66 years old, with
a mean age of (57 ± 7) years.
There were no significant differences between the three
groups in age and gender (P > 0.05) (Table 1).
Treatment protocols
Combined group: Sanhuangyilong decoction com-
bined with methotrexate tablets (MTX) taken orally.
The composition of the decoction was follows:
Huangqin (Radix Scutellariae Baicalensis) 15 g, Huan-
glian (Rhizoma Coptidis) 15 g, Huangbai (Cortex Phello-
dendri Amurensis) 15 g, Qinjiao (Radix Gentianae Mac-
rophyllae) 30 g, Weilingxian (Radix et Rhizoma Clemati-
dis Chinensis) 30 g, Baishao (Radix Paeoniae Alba) 30 g,
Xixin (Herba Asari Mandshurici) 6 g, Dilong (Phereti-
ma Aspergillum) 10 g, and Fuling (Poria) 30 g, de-
cocted in the TCM Dispensary of the General Hospi-
tal of Chengdu Military Region in China with an au-
tomatic decoction machine. The oral prescription
was for 100 mL, three times a day. The methotrexate
tablets were from Shanghai Xinyi Pharmaceutical
Co., Ltd., No. H31020644; 2.5-mg tablets were ad-
ministered in a 10-15 mg dose once per week. The
MTX group was treated with oral methotrexate tab-
lets. The two groups had 2 weeks as 1 course of
treatment with continuous observation for 2 courses.
During the treatment, the two groups were given di-
clofenac sodium sustained release tablets (75-mg
Voltaren tablets, Beijing Novartis, No. H10980297;
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dosage 75 mg orally, 2 times daily) for 4 weeks. When
necessary, the treatment course was altered with
5-mg prednisone tablets (Henan Topfond Pharmaceu-
tical Co., Ltd., No. H41020283; dosage: 2.5 mg oral-
ly, three times daily).
Observation index and method
The specimen collection was performed as follows: the
specimens were collected before the treatment and af-
ter 2 weeks and 4 weeks of the treatment; 2-3 mL sam-
ples of peripheral blood were collected from the RA pa-
tients and healthy controls in the morning (with an
empty stomach) before and after the treatment; the
samples were centrifuged at 3000 r/min for 10 min;
the upper serum was aspirated and the desired sample
was stored at－80 ℃. The synovial fluids from the RA
and OA patients were obtained by a lateral patellar
with a 5 mL syringe needle and stored at －80 ℃ for
centralised detection. TNF-α and IFN-gamma detec-
tion was performed with an enzyme-linked immuno-
sorbent assay (ELISA) in a kit purchased from Sichuan
RuiSheng Technology Co., Ltd. ESR levels were detect-
ed by the Westergren method and expressed as mm/h.
CRP levels were assayed using an automatic rate nephe-
lometic immunoassay and expressed as mg/L. The ref-
erence values were 0-15 mm/h for ESR and 0-3 mg/L
for CRP. DAS28 consists of human 28 joint tenderness
counts, swelling counts, the ESR or CRP level and the
patient's comprehensive assessment project, and the
disease activity is divided into the following four levels:
remission ( < 2.6), mild activity (2.6-3.2), moderate ac-
tivity (3.2-5.1) and severe activity (> 5.1).
Statistical analysis
SPSS11.5 statistical analysis software (SPSS, Inc., Chi-
cago, IL, USA) was used for the statistical analysis, and
the data are represented in`mean ± standard deviation
( xˉ ± s). The comparisons between the groups were
tested by a paired-samples T-test, and the analysis of
the correlation between the indicators was performed
by Pearson's correlation analysis. A P value < 0.05 was
considered statistically significant.
RESULTS
Study recruitment and follow-up
Of the initial 118 participants, 90 were considered eli-
gible and randomized to a group (Figure 1). The main
reasons for in ineligibility were failing to obtain a sam-
ple during treatment, detecting the emergence of com-
plications and poor patient compliance. Patients were
randomized to the combined group (n = 45), MTX
group (n = 45). All participants were followed up at 4
weeks.
Comparison of the expression level of TNF-α in
various groups
Compared with the healthy control group, the TNF-α
expression level in the peripheral blood of RA patients
was significantly higher (t = 8.758, P < 0.05); com-
pared with the synovial fluids from the patients with
OA, the expression of TNF-α was significantly higher
synovial fluid of RA patients (t = 2.51, P < 0.05); com-
pared with the peripheral blood of patients with RA,
the expression of TNF-α was significantly higher in
the synovial fluid of RA patients (t = 2.496, P < 0.05;
Figure 2A, Table 2).
Comparison of the expression level of IFN-γ in all
groups
Compared with the healthy control group, the IFN-γ
expression level in the peripheral blood of RA patients
significantly higher (t = 6.086, P < 0.05); compared
with the synovial fluids from the patients with OA, the
expression of IFN-γ was significantly higher in the sy-
novial fluid of RA patients (t = 2.523, P < 0.05); com-
pared with the peripheral blood of patients with RA,
the expression of IFN-γ was significantly higher in the
synovial fluid of RA patients (t = 2.708, P < 0.05; Fig-
ure2B, Table 2).
Correlation analysis between the expression level of
TNF-α, IFN-γ in RA serum and ESR, CRP, and
DAS28
Pearson's correlation analysis showed that there is no
correlation between the expression level of TNF-α in
RA serum and ESR levels, CRP levels, or DAS28
score (r =－0.108,－0.225,－0.228; P > 0.05); there
is no correlation between the expression level of se-
rum IFN-γ and ESR levels, CRP levels, or DAS28
score (r = － 0.104, r = － 0.285, r = － 0.414, P >
0.05).
Table 1 Comparison of the general data of the patients ( xˉ ± s)
Category
Cases (n)
Male/Female (n)
Age (years)
RA patients group
Combined group
45
7/38a
56±8a
MTX group
45
8/37 b
55±8b
Healthy control group
30
4/26
55±7
OA control group
30
3/27
57±7
Notes: combined group was treated with Sanhuangyilong decoction (100 mL, three times a day) combined with methotrexate tablets
(10 -15 mg , once per week). MTX group was treated with methotrexate tablets (10-15 mg, once per week). The two groups were treated
4 weeks. Healthy Control group: age-and sex-matched healthy persons. OA Synovial Fluid group: age-and sex-matched osteoarthritis pa-
tients with knee joint synovial fluid. RA: rheumatoid arthritis; MTX: methotrexate; OA: osteoarthritis. Combined group compared with
the healthy control group and the OA control group, there are no significant differences in sex and age, aP > 0.05. MTX group compared
with the healthy control group and the OA control group, there are no significant differences in sex and age, bP > 0.05.
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Correlation between the expression level of TNF-α,
IFN-γ in RA synovial fluid and ESR, CRP, DAS28
Pearson's correlation analysis showed no correlation be-
tween the expression level of TNF-α in RA synovial
fluid and ESR levels, CRP levels, or DAS28 score (r =
－0.256, 0.177;－0.65, P > 0.05); there is no correla-
tion between the expression level of synovial fluid
IFN-γ and ESR levels, CRP levels, or DAS28 score
(CRP, r = － 0.199, r = － 0.412, r = － 0.015, P >
0.05).
Comparison of the expression level of TNF-α and
IFN-γ before and after treatment in RA patients
After 2 weeks, TNF-α and IFN-γ expression levels
were increased in the combined group and the MTX
group compared with the identical group before treat-
ment; however, the differences were not statistically
significant (P > 0.05); likewise, differences between
the combined and MTX groups were not significant
(P > 0.05). After 4 weeks, compared with those be-
fore treatment, TNF-α and IFN-γ expression levels
significantly decreased in the combined group and
MTX group (P < 0.01); in addition, there was a
significant difference in the levels between the com-
bined and MTX groups (P < 0.01) (Figure 3, Ta-
ble 3).
Comparison of inflammatory changes before and
after treatment in patients with RA
At 2 weeks and 4 weeks, compared with the levels be-
fore treatment, ESR levels, CRP levels, and DAS28
scores were significantly decreased in the combined
group and the MTX group (P < 0.01 or P < 0.05). At
2 weeks and 4 weeks, the ESR levels, CRP levels, or
DAS28 scores were significantly different between the
combined and MTX groups (P < 0.05 or P < 0.01; Fig-
ure 4, Table 4).
DISCUSSION
The results of this study show that the serum TNF-α
and IFN-γ levels in RA patients with damp-heat-ob-
struction symptom patternwere significantly higher
than those in the healthy control group and that the
synovial fluid TNF-α and IFN-γ levels were signifi-
cantly higher than those in the peripheral blood and
osteoarthritis synovial fluid. The expression of
TNF-α and IFN in the serum of the peripheral
blood and synovial fluid has no obvious correlation
with ESR levels, CRP levels, or DAS28 score. Other
studies have reported that the TNF-α levels in the
peripheral blood and synovial fluid in RA patients
were significantly higher than those in the healthy
control group.22 The TNF-α levels in the synovial flu-
id of knee joints in RA children have also been
shown to be significantly higher than those in
healthy children, and there is no correlation between
TNF-α levels and peripheral blood WBC, ESR, CRP
or immunoglobulin levels.23 The serum IFN-γ levels
of RA patients in the active phase were significantly
Assessed for eligibility (n = 118)
Excluded (n = 28)
Not meeting inclusion criteria
(n = 5)
Declined to participate (n = 10)
Other reasons (n = 13)
Randomized groups (n = 2)
(n = 90)
Allocated to experimental group (n=45)
Received allocated intervention (n=45)
Allocated to controlled group (n = 45)
Received allocated intervention (n = 45)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Analysed (n = 45)
Excluded from analysis (n = 0)
Analysed (n = 45)
Excluded from analysis (n = 0)
Figure 1 Study participant flow diagram
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higher than those of RA patients in the stable phase,24
and they were significantly increased compared to
healthy controls.25,26 The results of this study are con-
sistent with those reported in the literature.
The results of this study suggest that for RA patients
with damp heat obstruction symptom pattern, after
the initial 2 weeks of treatment with Sanhuangyilong
decoction combined with the antirheumatic drug
methotrexate, in tablet form, the expression levels of
serum TNF-α and IFN-γ were increased. ESR levels,
CRP levels, and DAS28 score, all of which are in-
flammatory markers, were significantly reduced, and
the symptoms and signs of the patients improved sig-
nificantly. After 4 weeks of treatment, the levels of
TNF-α, IFN-γ, ESR and CRP as well as the DAS28
scores were significantly decreased in the combined
treatment group. Studies in other countries reported
that in RA patients treated with etanercept, the IL-6,
IL-1 and CRP levels decreased rapidly; however, the
TNF-α and sTNFR-Ⅱ increased markedly within
24 h, plateauing after 2 weeks.27 This result might be
because the synovial fluid of patients in the active
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Figure 3 Expression levels of TNF-α, IFN-γ in the serum be-
fore and after treatment between the two groups
A: TNF-α; B: IFN-γ. Combined group was treated with San-
huangyilong decoction (100 mL, three times a day) com-
bined with methotrexate tablets (10-15 mg, once per week)
and diclofenac sodium sustained release tablets (75 mg, 2
times daily) or prednisone tablets (2.5 mg, 3 times daily).
MTX group was treated with methotrexate tablets (10-15
mg , once per week) and diclofenac sodium sustained re-
lease tablets (75 mg, 2 times daily) or prednisone tablets
(2.5 mg, 3 times daily). MTX: methotrexate; TNF-α: tumor ne-
crosis factor-alpha; IFN-γ: interferon-gamma. After 2 weeks,
compared with before treatment, aP > 0.05; After 4 weeks,
compared with before treatment, bP < 0.01; compared with
MTX group, cP < 0.01.
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Figue 2 Expression levels of TNF-α, IFN-γ in the serum, syno-
vial fluid in all groups
A: TNF-α; B: IFN-γ. RA patients group: comprised 90 RA pa-
tients. Healthy control group: included 30 age-and sex-
matched healthy persons. RA synovial fluid group: com-
prised 28 RA patients with knee joint synovial fluid. OA syno-
vial fluid group: included 30 age-and sex-matched osteoar-
thritis patients with knee joint synovial fluid. RA: rheuma-
toid arthritis; OA: osteoarthritis; TNF-α: tumor necrosis fac-
tor-alpha; IFN-γ: interferon-gamma. Compared with the
healthy control group, aP < 0.05; compared with OA Synovial
Fluid, bP < 0.05; compared with RA patients, cP < 0.05.
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Table 2 Comparison of the expression level of TNF-α, IFN-γ
in all groups (pg/mL, xˉ ± s)
Group
RA Patients
Healthy Control
RA Synovial Fluid
OA Synovial Fluid
n
90
30
28
30
TNF-α
40.0±17.0a,c
5.1±1.6
68.7±31.6b
48.0±16.7
IFN-γ
317.6±163.5a,c
69.6±32.2
1723.1±1421.3b
450.2±126.5
Notes: RA patients group: comprised 90 RA patients. Healthy
Control group: included 30 age-and sex-matched healthy per-
sons. RA Synovial Fluid group: comprised 28 RA patients with
knee joint synovial fluid. OA Synovial Fluid group: included 30
age-and sex-matched osteoarthritis patients with knee joint syno-
vial fluid. TNF-α: tumor necrosis factor-alpha; IFN-γ: interfer-
on-gamma; RA: rheumatoid arthritis; OA: osteoarthritis. Com-
pared with the healthy control group, aP < 0.05; compared with
OA Synovial Fluid, bP < 0.05; compared with RA Synovial Flu-
id, cP < 0.05.
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Figure 4 Comparison of the ESR levels, CRP levels, and DAS28 score before and after treatment in the patients with RA
Combined group was treated with Sanhuangyilong decoction (100 mL, three times a day) combined with methotrexate tab-
lets (10-15 mg, once per week) and diclofenac sodium sustained release tablets (75 mg, 2 times daily) or prednisone tablets
(2.5 mg, 3 times daily). MTX group was treated with methotrexate tablets (10-15 mg, once per week) and diclofenac sodium
sustained release tablets (75 mg, 2 times daily) or prednisone tablets (2.5 mg, 3 times daily). MTX: methotrexate; ESR: erythro-
cyte sedimentation rate; CRP: C-reactive protein; DAS28: disease activity score in 28 joints.
Table 3 Comparison of the expression level of TNF-α, IFN-γ before and after treatment in RA patients (pg/mL, xˉ ± s)
Group
Combined
MTX
Phase
Before treatment
2 weeks of treatment
4 weeks of treatment
Before treatment
2 weeks of treatment
4 weeks of treatment
n
45
45
45
45
45
45
TNF-α
40±17
42±13a
10±5bc
40±17
41±10a
19±9b
IFN-γ
318±163
445±335a
97±33bc
332±166
386±317a
176±146b
Notes: combined group was treated with Sanhuangyilong decoction (100 mL, three times a day) combined with methotrexate tablets
(10-15 mg, once per week) and diclofenac sodium sustained release tablets (75 mg, 2 times daily) or prednisone tablets (2.5 mg, 3 times
daily). MTX group was treated withmethotrexate tablets (10-15mg , once per week) and diclofenac sodium sustained release tablets (75 mg, 2
times daily) or prednisone tablets (2.5 mg, 3 times daily). MTX: methotrexate; TNF-α: Tumor Necrosis Factor-alpha; IFN-γ: Interfer-
on-gamma. After 2 weeks, compared with before treatment,aP > 0.05; After 4 weeks, compared with before treatment, bP< 0.01; compared
with MTX group, cP < 0.01.
Table 4 Comparison of the ESR levels, CRP levels, and DAS28 score before and after treatment in the patients with RA ( xˉ ± s)
Group
Combined
MTX
Phase
Before treatment
2 weeks of treatment
4 weeks of treatment
Before treatment
2 weeks of treatment
4 weeks of treatment
n
45
45
45
45
45
45
ESR (mm/h)
60.6±34.4
33.3±29.2ac
13.3±10.6ad
61.1±33.8
40.9±30.6b
29.6±28.6a
CRP (mg/L)
73.9±60.2
18.2±19.1ac
4.4±3.3ad
74.4±59.7
55.1±34.2b
17.9±15.2a
DAS28
7.0±0.8
3.4±1.2ac
1.9±0.4ad
7.1±0.9
5.3±2.1b
3.0±1.0a
Notes: combined group was treated with Sanhuangyilong decoction (100 mL, three times a day) combined with methotrexate tablets
(10-15 mg , once per week)and diclofenac sodium sustained release tablets (75 mg, 2 times daily) or prednisone tablets (2.5 mg, 3
times daily). MTX group was treated with methotrexate tablets (10-15 mg, once per week) and diclofenac sodium sustained release
tablets (75 mg, 2 times daily) or prednisone tablets (2.5 mg, 3 times daily). MTX: methotrexate; ESR: erythrocyte sedimentation rate;
CRP: C-reactive protein; DAS28: disease activity score in 28 joints. At 2 weeks and 4 weeks, compared with the levels before treat-
ment, ESR levels, CRP levels and DAS28 were significantly decreased in the combined group and MTX group, aP < 0.01, or bP <
0.05. At the corresponding time, ESR levels, CRP levels, or DAS28 scores in the combined group were significantly decreased in
MTX group, cP < 0.05, or dP < 0.01.
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disease stage stores a large number of cytokines that
quickly migrate to serum after sudden drug stimula-
tion and exhibit a growing trend for cytokines in se-
rum after only a short time. RA patients with
damp-heat-obstruction symptom pattern have a yang
deficiency of the spleen and kidney, and pathogenic
damp heat invades the body, brews cementation and is
difficult to eliminate quickly, resulting in joint inflam-
mation. The TNF-α and IFN-γ cytokines in serum
and synovial fluid, with internal and external factors,
might non-specifically activate T and B lymphocytes
and mediate autoimmune injury. After treatment
with the San Jiao bitter cold dampness prescription,
which clears heat and eliminates dampness, activates
collaterals, and relieves pain, immunosuppressive ther-
apy combined with MTX could rapidly stimulate the
accumulation of cytokines in serum; however, the ac-
cumulation could be quickly reduced by the continu-
ous anti-inflammatory action of the drugs. After the
inflammatory activities are controlled, a satisfactory
effect could be quickly achieved.
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